Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Additional Information (Detail)

v3.4.0.3
Licenses Acquired - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 11, 2016
May. 11, 2015
Apr. 02, 2015
Feb. 29, 2016
Oct. 31, 2015
Sep. 30, 2015
Jul. 16, 2015
Jun. 17, 2015
May. 31, 2015
Apr. 28, 2015
Mar. 17, 2015
Feb. 28, 2015
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Feb. 17, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments to Acquire Intangible Assets                         $ 200,000 $ 1,250,000    
Research And Development In Process                         83,000 7,439,000    
Stock Issued During Period, Value, Issued for Services                         2,000 1,000    
Research And Development Expense                         $ 7,736,000 1,642,000    
Share Price                         $ 9.61      
Reimbursment Of Cost Recognised As Revenue $ 300,000                       $ 300,000      
NeuPharma [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Research And Development In Process                     $ 1,000,000          
City Of Hope [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Marketability Percentage Of Invested Capital                             44.80%  
Payments for Fees                             $ 2,000,000  
Stock Issued During Period, Shares, Other                             1,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent                             30.00%  
Share Price                             $ 0.147  
Stock Issued During Period, Value, Other                             $ 100,000  
National Institutes of Health [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payment of Upfront Milestone Fees             $ 700,000                  
New Zealand Pharmaceuticals Ltd [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Reimbursement Revenue             600,000                  
Dana-Farber [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Shares Issued, Price Per Share   $ 0.065       $ 4.39                    
Stock Issued During Period, Shares, Issued for Services   500,000       136,803                    
Stock Issued During Period, Value, Issued for Services   $ 32,500       $ 600,000                    
Escala Therapeutics, Inc [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payment of Upfront Fees             $ 1,300,000                  
Collaboration Agreement with TGTX [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments for Fees                         17,000,000,000 500,000 500,000  
Collaboration Agreement with TGTX [Member] | NeuPharma [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments for Fees                             25,000  
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments for Fees                         17,000   500,000  
Coronado SO Co, Inc [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Research And Development In Process                         $ 0 $ 1,179,000    
Payments for Fees                       $ 900,000        
Stock Issued During Period, Shares, Other                       150,000        
Research And Development Expense         $ 500,000                      
Licensing Agreements [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments to Acquire Intangible Assets     $ 150,000 $ 35,000           $ 50,000            
Intangible Assets, Net (Excluding Goodwill), Total                             $ 500,000  
Licensing Agreements [Member] | City Of Hope [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Marketability Percentage Of Invested Capital                         44.50%      
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent                         30.00%      
Share Price                         $ 0.097      
Stock Issued During Period, Value, Other                         $ 48,500      
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued                         500,000      
Licensing Agreements [Member] | Dana-Farber [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments for Fees                 $ 1,000,000              
Licensing Agreements [Member] | Coronado SO [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Marketability Percentage Of Invested Capital         44.80%                      
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent         30.00%                      
Share Price         $ 1.19                      
Licensing Agreements [Member] | IV Tramadol [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments to Acquire Intangible Assets               $ 1,000,000                
Payments for Fees                       $ 2,000,000        
Avenue Therapeutics, Inc. [Member]                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Shares Issued, Price Per Share                             $ 0.146  
Research And Development Expense                         $ 5,000      
Debt Instrument, Fee Amount                               $ 3,000,000